Associate Professor, Medicine, U of WA Sch of Med
Hematology
Dr. Elena G. Chiorean, MD
|
|
Give Review
Elena Chiorean is an expert in the field of Hematology. Elena Chiorean is also a published physician. She has 39 publication published. The most recent publication is: Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Algenpantucel-L immunotherapy in pancreatic adenoCarcinoma.
- Metabolomics method to comprehensively Analyze amino acids in different domains.
- Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic p...
- A phase I first-in-human study of enoticumab (REGN421), a fully-human Delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid Tumors.
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer.
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
- Colorectal Cancer detection using targeted serum metabolic profiling.
- AntiCancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
- Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer.
- A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid Tumors.
- Taxanes: impact on pancreatic Cancer.
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.
- A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic Ductal adenocarcinoma.
- Elevated phospholipase A2 activities in plasma samples from multiple Cancers.
- Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid Tumors.
- A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid Tumors.
- Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic Cancer: a phase 2 study.
- Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors.
- A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer: A Hoosier Oncology Group Study.
- Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy.
- CD40 agonists alter tumor stroma and show efficacy against pancreatic Carcinoma in mice and humans.
- Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
- Pancreatic Cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
- A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenoCarcinoma.
- Non-ampullary duodenal adenoCarcinoma: factors important for relapse and survival.
- Locally advanced pancreatic Cancer: current therapeutic approach.
- Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous Leukemia after allogeneic hematopoietic cell transplantation.
- Trastuzumab and interleukin-2 in HER2-positive metastatic breast Cancer: a pilot study.
- BCR/ABL alters the function of NK Cells and the acquisition of killer immunoglobulin-like receptors (KIRs).
- Contribution of environment and genetics to pancreatic Cancer susceptibility.
- PR-104 plus sorafenib in patients with advanced hepatocellular Carcinoma.
- Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth fact...
- Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic Cancers.
- A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenoCarcinoma.
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies.
- A phase I study of sunitinib plus capecitabine in patients with advanced solid Tumors.
- A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid Tumors.
- A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Schools
Universitatea De Medicina Si Farmacie TirguMures Facultatea De Medicina
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Minnesota -
William Beaumont Hospital -
Iuliu Hatieganu University of Medicine and Pharmacy
Drug Facts
| NPI NUMBER | 1891750808 | |
| NPPES Provider LastName | CHIOREAN | |
| NPPES Provider FirstName | ELENA | |
| NPPES Provider ZIPCode | 981094405 | |
| NPPES Provider State | WA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 205.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 5.37 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891750808 |
| Last Name Of The Provider | CHIOREAN |
| First Name Of The Provider | ELENA |
| View All |
Similar Doctors
|
|
Mohammad I. Abu Zaid, MB BS |
|
|
Dr. Rebecca W. Silbermann, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Greist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noah M. Hahn, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kathy D. Miller, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Robert Haerr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madelaine M. Sgroi, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Radhika V. Walling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caroline S. An, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Gray, MD |
|
|
Dr. Eric H. Westin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gregory W. Smith, MD |
|
|
Dr. Shivani Srivastava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose M. Azar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sherif S. Farag, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fredrick C. Asirwa, MD
This Doctor is OpenDoctor Recommended.
|